The pharmacology of endothelin and its antagonist bosentan;La pharmacologie de l'endotheline et de son antagoniste bosentan

Annales d'Endocrinologie

Volumn 61, Issue 1, 2000, Pages 75-79

  Clozel, M ^a   Roux, S ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Bosentan; Endothelin; Endothelin receptors; Essential hypertension; Heart failure; Pulmonary hypertension

Indexed keywords

BOSENTAN; ENDOTHELIN; ENDOTHELIN RECEPTOR; SULFONAMIDE;

CONFERENCE PAPER; ESSENTIAL HYPERTENSION; FIBROSIS; HEART FAILURE; HYPERTROPHY; INFLAMMATION; PULMONARY HYPERTENSION; VASOCONSTRICTION; ANIMAL; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; HUMAN; HYPERTENSION; PHYSIOLOGY; REVIEW;

ANIMALS; ENDOTHELINS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; HYPERTENSION, PULMONARY; RECEPTORS, ENDOTHELIN; SULFONAMIDES;

EID: 0034057845     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (37)

1. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990 ; 348 : 730-2.
2. Chen SJ, Chen YF, Meng QC et al. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995 ; 79 : 2122-31.
3. Clozel M, Breu V, Gray GA et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994 ; 270 : 228-35.
4. Clozel M, Gray GA, Breu V, Loffler BM, Osterwalder R. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res commun 1992 ; 186 : 867-73.
5. Eddahibi S, Raffestin B, Clozel M, Levame M, Adnot S. Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats. Am J Physiol 1995 ; 268 : H828-35.
6. Filep JG, Fournier A, Foldes-Filep E. Acute pro in flammatory actions of endothelin-1 in the guinea-pig lung : involvement of ETA and ETB receptors. Br J Pharmacol 1995 ; 115 : 227-36.
7. Giaid A, Yanagisawa M, Langleben D et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993 ; 328 : 1732-9.
8. Gurbanov K, Rubinstein I, Hoffman A et al. Bosentan improves renal regional blood flow in rats with experimental congestive heart failure. Eur J Pharmacol 1996 ; 310 : 193-6.
9. Harada M, Itoh H, Nakagawa O et al. Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy : evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes. Circulation 1997 ; 96 : 3737-44.
10. Hess P, Clozel M, Clozel JP. Telemetry monitoring of pulmonary arterial pressure in freely moving rats. J Appl Physiol 1996 ; 81 : 1027-32.
11. Ishikawa S, Miyauchi T, Ueno H et al. Influence of pulmonary blood pressure and flow on endothelin-1 production in humans. J Cardiovasc Pharmacol 1995 ; 26 : 429-33.
12. Karam H, Heudes D, Gonzales MF et al. Respective role of humoral factors and blood pressure in aortic remodeling of DOCA hypertensive rats. Am J Hypertens 1996 ; 9 : 991-8.
13. Katwa LC, Guarda E, Weber KT. Endothelin receptors in cultured adult rat cardiac fibroblasts. Cardiovasc Res 1993 ; 27 : 2125-9.
14. Kiowski W, Sutsch G, Hunziker P et al. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet 1995 ; 346 : 732-6.
15. Krum H, Goldsmith R, Wilshire-Clement M, Miller M, Packer M. Role of endothelin in the exercise intolerance of chronic heart failure. Am J Cardiol 1995 ; 75 : 1282-3.
16. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 1998 ; 338 : 784-90.
17. B receptors coexist on rabbit pulmonary artery vascular smooth muscle mediating contraction. Biochem Biophys Res commun 1993 ; 196 : 209-15.
18. Lerman A, Edwards BS, Hallett JW et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991 ; 325 : 997-1001.
19. Li JS, Lariviere R, Schiffrin EL. Effect of a nonselective endothel in antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 1994 ; 24 : 183-8.
20. Li JS, Schurch W, Schiffrin EL. Renal and vascular effects of chronic endothelin receptor antagonism in malignant hypertensive rats. Am J Hyoertens 1996 ; 9 : 803-11.
21. Loffler BM, Breu V, Clozel M. Effect of different endothel in receptor antagonists and of the novel non-peptide antagonist Ro 46-2005 on endothelin levels in rat plasma. FEBS Lett 1993 ; 333 : 108-10.
22. MacLean MR, McGrath JC. Effects of pre-contraction with endothelin-1 on alpha 2-adrenoceptor-and (endothelium-dependent) neuropeptide Y-mediated contractions in the isolated vascular bed of the rat tail. Br J Pharmacol 1990 ; 101 : 205-11.
23. Mulder P, Richard V, Derumeaux G et al. Role of endogenous endothelin in chronic heart failure : effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997 ; 96 : 1976-82.
24. Nakayama K, Ishigai Y, Uchida H, Tanaka Y. Potentiation by endothelin-1 of 5-hydroxytryptamine-induced contraction in coronary artery of the pig. Br J Pharmacol 1991 ; 104 : 978-86.
25. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction [see comments]. Circulation 1994 ; 89 : 1573-9.
26. Pousset F, Isnard R, Lechat P et al. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 1997 ; 18 : 254-8.
27. Rossi GP, Albertin G, Neri G et al. Endothelin-1 stimulates steroid secretion of human adrenocortical cells ex vivo via both ETA and ETB receptor subtypes. J Clin Endocrinol Metab 1997 ; 82 ; 3445-9.
28. Rubanyi GM, Polokoff MA. Endothelins : Molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol Rev 1994 ; 46 : 328-415.
29. Sakurai T, Yanagisawa M, Takuwa Y et al. Cloning of a cDNA encoding a non-isopeptide selective subtype of the endothelin receptor. Nature 1990 ; 348 ; 732-5.
30. B receptors mediate contraction to endothelinin human blood vessels. Circulation 1994 ; 89 : 1203-8.
31. Shimoyama H, Sabbah HN, Borzak S et al. Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure. Circulation 1996 ; 94 : 779-84.
32. B receptors mediate vascular smooth muscle contraction. Br J Pharmacol 1992 ; 107 : 858-60.
33. Sutsch G, Kiowski W, Yan XW et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998 ; 98 : 2262-8.
34. Teerlink JR, Loffler BM, Hess P et al. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation 1994 ; 90 : 2510-8.
35. Wagner OF, Christ G, Wotja J et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992 ; 267 : 16066-8.
36. Weber C, Schmitt R, Birnboeck H et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 1996 ; 60 : 124-37.
37. Yanagisawa MH, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988 ; 332 : 411-5.